This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold Medidata Stock in Your Portfolio
by Zacks Equity Research
Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.
Buy These 4 Efficient Stocks for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.
Omeros (OMER) Surges: Stock Moves 10.2% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.
Is Surmodics (SRDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRDX) Outperforming Other Medical Stocks This Year?
Intuitive Surgical and InTouch Collaborate for IoMT Services
by Zacks Equity Research
Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
GW Pharmaceuticals (GWPH) Catches Eye: Stock Jumps 5.9%
by Zacks Equity Research
GW Pharmaceuticals (GWPH) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Medical - Products Stock Outlook: Short-Term Pain Inevitable
by Zacks Equity Research
Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Why Is SurModics (SRDX) Up 19.9% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
by Zacks Equity Research
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
4 of the Best Efficient Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
by Zacks Equity Research
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
4 Winning Stocks With Solid Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
SurModics (SRDX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 437.50% and 12.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
by Zacks Equity Research
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
4 of the Best Efficient Stocks to Buy for Superb Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns